10q10k10q10k.net
Natera, Inc.

Natera, Inc.NTRAEarnings & Financial Report

Nasdaq

Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendment...

NextFeb 28, 2026

NTRA Q3 2025 Key Financial Metrics

Revenue

$592.2M

Gross Profit

N/A

Operating Profit

$-97.6M

Net Profit

$-87.5M

Gross Margin

N/A

Operating Margin

-16.5%

Net Margin

-14.8%

YoY Growth

34.7%

EPS

$-0.64

Financial Flow

Natera, Inc. Q3 2025 Financial Summary

Natera, Inc. reported revenue of $592.2M for Q3 2025, with a net profit of $-87.5M (-14.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$592.2M
Net Profit$-87.5M
Gross MarginN/A
Operating Margin-16.5%
Report PeriodQ3 2025

Natera, Inc. Annual Revenue by Year

Natera, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.7B).

YearAnnual Revenue
2024$1.7B
2023$1.1B
2022$820.2M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$311.1M$367.7M$413.4M$439.8M$476.1M$501.8M$546.6M$592.2M
YoY Growth43.2%52.1%58.1%63.9%53.0%36.5%32.2%34.7%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$1.44B$1.47B$1.52B$1.59B$1.66B$1.73B$1.76B$1.82B
Liabilities$676.4M$674.1M$680.5M$712.4M$465.3M$492.7M$510.9M$569.3M
Equity$765.3M$794.1M$836.5M$878.5M$1.20B$1.24B$1.25B$1.25B

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-58.1M$27.0M$4.0M$51.8M$52.9M$44.5M$37.6M$59.4M